Type II kinase inhibitors, including the BCR‐Abl inhibitors imatinib and nilotinib, are mainly used for the treatment of chronic myeloid leukemia (CML).213, 214. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.